Sun-Ranbaxy deal got conditional approval from CCI* CCI vide its order dated December 5, 2014 has conditionally approved the proposed merger between Sun Pharma and Ranbaxy (collectively called as “parties”), subject to the parties inter alia carrying out the divestiture of their products relating to seven relevant markets for formulations. This is the first time in the history of Indian Competition Law that CCI has ordered the sale of certain assets before approving a merger, wherein, parties have been directed to sell certain products before the merger can be made effective. After considering the response of both the parties to the show cause notice issued by CCI and the comments received from the members of the public on the proposed combination after the publication of details of
The Indian Competition Authority approves a merger of two global pharmaceutical companies subject to divestitures in seven markets for different formulations (Sun Pharma / Ranbaxy)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.